durvalumab
astrazeneca
#wcgic22 #hpbcsm topaz1 - ph3 cisp/gem +/- durva analysis by primary tumour location no significant difference in efficacy observed but ?suggests less benefit on gb vs intra- and extrahepatic cholangio
challenging to interpret given the inherent heterogeneity 
Cancer Doctor, Professor, Lifelong Learner  #GIcancer ???? @UBC @BCCancer @CCTG #Prez @CAMO #TEDxSpeaker #MedTwitter Tweets are my own